medRxiv · 31 Aug 2026 · Preprint · Open access

Deep Fascia Plane Dissection and Mattox Maneuver for Lymphadenectomy in Pancreatic Body-Tail Cancer: SEER-Based Evidence, Anatomical Rationale, and Quantitative Modeling

Ye, Wang + 5 more

Open access

Abstract ↗AI briefThe abstract is read at the publisher; the brief is JClub's.

The AI brief for this paper is being written. Open it in JClub to read the paper with the brief as soon as it lands.

Read the brief in JClub →

Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer.
Nature Medicine · 1 Aug 2026 · Clinical Trial, Phase II
Over 59% of pancreatic cancer patients treated with daraxonrasib develop resistance through RAS pathway alterations, including KRAS amplification and RTK upregulation.
- Open access
- 5 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42581230
Open in JClub
CDK8 remodels the tumor microenvironment and promotes resistance to KRAS(G12D) inhibitors and daraxonrasib in PDAC.
EMBO Journal · 1 Aug 2026 · Journal Article
CDK8 drives immune evasion and resistance in PDAC by remodeling the tumor microenvironment during KRAS G12D inhibition, with 50% of cases showing resistance.
- Open access
- 3 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42436354
Open in JClub
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer.
New England Journal of Medicine · 23 July 2026 · Randomized Controlled Trial
Daraxonrasib significantly improves overall survival and progression-free survival in previously treated metastatic pancreatic ductal adenocarcinoma, with median overall survival of 13.2 months versus 6.6 months for chemotherapy.
- 97 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42223072
Open in JClub

Journals this month

All journals →

Moving areas, week to 3 Oct 2026

All research areas →

Read